Editorial review · United States
Tirzepatide
Source review:
Approval and product status
Some FDA-approved tirzepatide products exist for specific uses
Mounjaro and Zepbound are distinct approved products. Their evidence and labels do not make every compounded or research-labeled tirzepatide product equivalent.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Strong
- Large randomized studies support blood-sugar, weight, and heart-risk results in specific groups.
- Body effects · Strong
- Studies have described how approved products enter and affect the body in detail.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
Current prescribing information contains a boxed warning and important contraindications, warnings, and precautions. This guide does not tell you whether a product is right for you. It does not recommend a product or give dosing or dose-change instructions.
Still unknown: The evidence does not show that tirzepatide gives everyone the same result. It does not establish a universal “metabolic reset,” longer life, or better athletic performance. Evidence for approved medicines does not make compounded, counterfeit, or research-labeled products equivalent to those medicines.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
Mounjaro
- Form
- Injection
- Route
- Subcutaneous
- Use and limits
- Blood-sugar control in defined type 2 diabetes populations. FDA approved a heart-risk reduction use for certain adults with type 2 diabetes on August 27, 2026.
Published label: January 2026 published label; August 27, 2026 supplement approval; revised label not yet posted
Read the published Mounjaro FDA label (PDF)Zepbound
- Form
- Injection
- Route
- Subcutaneous
- Use and limits
- Long-term weight management and moderate-to-severe obstructive sleep apnea in defined adults with obesity. An August 26, 2026 FDA supplement added cardiovascular-trial information, not a new use.
Published label: February 2026 published label; August 26, 2026 supplement letter
Read the published Zepbound FDA label (PDF)What the research shows
The studies looked at specific groups of people for set periods. FDA-reviewed labels and large randomized trials support blood-sugar, weight, and heart and blood-vessel outcomes in these groups. Mounjaro also has an FDA-approved heart-risk use. It can lower the risk of death from heart or blood-vessel disease, a nonfatal heart attack, or a nonfatal stroke. This use is for adults with type 2 diabetes who are at high risk. SURPASS-2 studied adults with type 2 diabetes. SURMOUNT-1 studied adults with obesity, or overweight with a related condition, who did not have diabetes. These study groups, comparisons, outcomes, and time periods set the limits of each result.
Read all Tirzepatide claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- MOUNJARO (tirzepatide) prescribing information, revised January 2026
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- ZEPBOUND (tirzepatide) prescribing information, revised February 2026
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- FDA approval letter: Mounjaro heart-risk indication, August 27, 2026
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- FDA supplement letter: Zepbound cardiovascular-trial information, August 26, 2026
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- FDA review: tirzepatide's 39-amino-acid structure
U.S. Food and Drug Administration · FDA review · 2022
Source accessed
- Tirzepatide once weekly for the treatment of obesity
PubMed · New England Journal of Medicine · Randomized trial · 2022
Source accessed
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
PubMed · New England Journal of Medicine · Randomized trial · 2021
Source accessed
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed